Strativa Pharmaceuticals, the Proprietary Products Division of Par Pharmaceutical, Provides an Update on Development ... (The San Francisco Examiner)
WOODCLIFF LAKE, N.J. ( Map ) - WOODCLIFF LAKE, N.J., Dec. 28 /PRNewswire-FirstCall/ -- Par Pharmaceutical Companies, Inc. (NYSE: PRX ) today provided an update on the development status of its three, in-licensed, proprietary pipeline products: pafuramidine, Loramyc(R) (miconazole Lauriad(R)), and Zensana(TM) (ondansetron).

'Optical Mammogram' Could Be Major Step Forward in Battle To Detect Breast Cancer (Local Tech Wire)
CHARLOTTE Editor's note: 'Charlotte Beat' will appear every Wednesday, focusing on an entrepreneur or company having an impact on the region's high-tech economy.